Q2 Earnings Estimate for SABS Issued By HC Wainwright

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for SAB Biotherapeutics in a research note issued to investors on Wednesday, May 14th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.58) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.85) EPS, FY2026 earnings at ($0.35) EPS, FY2027 earnings at ($0.25) EPS, FY2028 earnings at ($0.33) EPS and FY2029 earnings at ($0.42) EPS.

Separately, Chardan Capital restated a “buy” rating and set a $20.00 price objective on shares of SAB Biotherapeutics in a report on Thursday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $12.20.

SAB Biotherapeutics Trading Down 4.6%

NASDAQ SABS opened at $1.85 on Friday. The company has a market cap of $17.19 million, a price-to-earnings ratio of -0.50 and a beta of 0.47. SAB Biotherapeutics has a 52 week low of $1.00 and a 52 week high of $5.01. The business has a 50 day moving average price of $1.52 and a 200-day moving average price of $2.51. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Friday, May 9th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.44. SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. HB Wealth Management LLC boosted its position in shares of SAB Biotherapeutics by 10.9% during the first quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock valued at $358,000 after buying an additional 25,800 shares during the last quarter. Silver Oak Securities Incorporated purchased a new position in shares of SAB Biotherapeutics during the first quarter valued at approximately $30,000. Northern Trust Corp purchased a new position in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $43,000. Diadema Partners LP purchased a new position in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $114,000. Finally, Geode Capital Management LLC boosted its position in shares of SAB Biotherapeutics by 18.8% during the fourth quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after buying an additional 12,692 shares during the last quarter. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.